TG THERAPEUTICS INC (TGTX) — insider trading
Health Care · NASDAQ
TG THERAPEUTICS INC (TGTX) has 19 reported SEC Form 4 insider transactions in our data, including 4 open-market sales among the most recent 19 (latest 2026-09-10).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | Charney Laurence N | Director | Open-market sale | 5,000 | $54.96 | $274.8K | Form 4 |
| 2026-08-07 | Charney Laurence N | Director | Bona fide gift | 450 | — | $0 | Form 4 |
| 2026-08-07 | Charney Laurence N | Director | Bona fide gift | 500 | — | $0 | Form 4 |
| 2026-08-06 | Charney Laurence N | Director | Bona fide gift | 5,100 | — | $0 | Form 4 |
| 2026-06-11 | Charney Laurence N | Director | Grant / award / vesting (derivative) | 8,325 | — | $0 | Form 4 |
| 2026-06-11 | Echelard Yann | Director | Grant / award / vesting (derivative) | 8,325 | — | $0 | Form 4 |
| 2026-06-11 | Hoberman Kenneth | Director | Grant / award / vesting (derivative) | 8,325 | — | $0 | Form 4 |
| 2026-06-11 | HUME DANIEL | Director | Grant / award / vesting (derivative) | 8,325 | — | $0 | Form 4 |
| 2026-06-11 | Lonial Sagar | Director | Grant / award / vesting (derivative) | 8,325 | — | $0 | Form 4 |
| 2026-01-29 | Charney Laurence N | Director | Bona fide gift | 13,197 | — | $0 | Form 4 |
| 2026-01-28 | Charney Laurence N | Director | Bona fide gift | 30,000 | — | $0 | Form 4 |
| 2026-01-08 | Power Sean A | Officer (CFO) | Grant / award / vesting | 90,000 | — | $0 | Form 4 |
| 2026-01-08 | WEISS MICHAEL S | Director, Officer (CEO) | Grant / award / vesting | 622,000 | — | $0 | Form 4 |
| 2025-11-24 | Echelard Yann | Director | Open-market sale | 5,000 | $32.57 | $162.8K | Form 4 |
| 2025-11-05 | WEISS MICHAEL S | Director, Officer (CEO) | Bona fide gift | 803,717 | — | $0 | Form 4 |
| 2025-11-05 | WEISS MICHAEL S | Director, Officer (CEO) | Bona fide gift | 3,865,126 | — | $0 | Form 4 |
| 2025-09-11 | Lonial Sagar | Director | Open-market sale | 20,852 | $32.24 | $672.3K | Form 4 |
| 2025-06-13 | Echelard Yann | Director | Open-market sale | 10,000 | $36.94 | $369.4K | Form 4 |
| 2025-06-12 | Echelard Yann | Director | Grant / award / vesting | 14,718 | — | $0 | Form 4 |
Ask the chat about TGTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: TG THERAPEUTICS INC (TGTX).
Last updated 2026-09-10 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.